Makro-Albumon (Macrosalb (99mtc))

Makro-Albumon is an intravenous albumin solution used in conditions where plasma oncotic pressure support is needed.

• Hypoalbuminemia: helps restore normal serum albumin levels and oncotic pressure.
• Acute volume depletion: contributes to plasma volume expansion during shock or major surgery.
• Liver disease with ascites: may be used to manage fluid balance in selected patients.

• Macrosalb acts as a plasma protein replacement, increasing oncotic pressure within the vascular compartment. By expanding intravascular volume, it improves tissue perfusion and facilitates transport of endogenous substances such as hormones, drugs, and fatty acids. The molecule binds calcium and other ions, contributing to hemostasis and acid‑base balance.

Makro-Albumon, like other albumin solutions, may be associated with adverse reactions.

Common Side Effects

• Fever or chills during infusion.
• Mild hypotension or transient blood pressure changes.
• Headache or dizziness.
• Nausea or mild gastrointestinal discomfort.
• Local irritation at the infusion site.
• Transient increase in serum calcium levels.

Serious or Rare Side Effects

• Anaphylactic or severe allergic reactions.
• Volume overload leading to pulmonary edema.
• Cardiac arrhythmias in susceptible patients.
• Hemolysis or red blood cell aggregation.
• Severe electrolyte disturbances.
• Coagulopathy or bleeding complications.

Before using Makro-Albumon, consider the following safety measures.

• Assess fluid status: evaluate for signs of overload or dehydration.
• Cardiac function: monitor patients with heart failure or coronary disease.
• Renal impairment: adjust volume administration in patients with reduced kidney function.
• Electrolyte balance: check serum calcium and potassium levels prior to infusion.
• Allergic history: verify no prior severe reactions to albumin products.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Makro-Albumon may interact with other agents affecting fluid balance or coagulation.

Major Interactions (Avoid)

• Diuretics: concurrent use can exacerbate hypovolemia.
• ACE inhibitors or ARBs: may increase risk of hypotension.
• Anticoagulants: albumin can alter plasma protein binding, affecting drug levels.

Moderate Interactions (Monitor Closely)

• Calcium channel blockers: monitor for additive blood pressure effects.
• Immunosuppressants: observe for changes in drug pharmacokinetics.
• Other plasma expanders: avoid cumulative volume overload.